articleAllergyJan 8, 2024HYBRID OA

Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

SMSvenja MüllerLMLaura MaintzTBThomas Bieber

University Hospital Bonn · CK-CARE

PubMed
Indexed incrossrefpubmed

Abstract

Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti-interleukin-4 receptor (IL-4R) α in 2017), tralokinumab (anti-IL-13 in 2021), lebrikizumab (anti-IL-13 in 2023), and the oral janus kinase (JAK) inhibitors (JAKi) targeting JAK1/2 (baricitinib in 2020 in the EU) or JAK1 (upadacitinib in 2021 and abrocitinib in 2022). Herein, we give an update on new approvals, long-term safety, and efficacy. Upadacitinib and abrocitinib have the highest short-term efficacy among the approved systemic therapies. In responders, dupilumab and…

Citation impact

127
total citations
FWCI
61.22
Percentile
100%
References
146
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • Dupilumab
  • Medicine
  • Atopic dermatitis
  • Ruxolitinib
  • Clinical trial
  • Pharmacology
  • Internal medicine
  • Dermatology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding